Jonathan Alspaugh - Feb 23, 2023 Form 4 Insider Report for Aeglea BioTherapeutics, Inc. (AGLE)

Role
Chief Financial Officer
Signature
/s/ James Kastenmayer, by power of attorney
Stock symbol
AGLE
Transactions as of
Feb 23, 2023
Transactions value $
$0
Form type
4
Date filed
2/24/2023, 05:20 PM
Previous filing
Aug 25, 2022
Next filing
Jun 30, 2023

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AGLE Employee Stock Option (right to buy) Award $0 +640K $0.00 640K Feb 23, 2023 Common Stock 640K $0.44 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The stock option vests and becomes exercisable in 48 equal monthly installments beginning on March 23, 2023, until such time as the option is 100% vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.